The Rate of Referral of Hepatitis Virus Carriers to Hepatologists and the Factors Contributing to Referral

Kazuhide Takata1,2, Akira Anan2, Daisuke Morihara2, Kaoru Yotsumoto1, Kunitoshi Sakurai1, Atsushi Fukunaga2, Takashi Tanaka2, Keiji Yokoyama2, Yasuaki Takeyama3, Makoto Irie2, Satoshi Shakado2, Tetsuro Sohda2 and Shotaro Sakisaka2

Abstract

Objective The aims of the present study were to determine the proportions of hepatitis B surface antigen (HBsAg)-positive and anti-hepatitis C virus (HCV)-positive patients, and identify the characteristics that influenced referral to a hepatologist.

Methods The present study included patients who were positive for HBsAg (n=153) or anti-HCV (n=574); their viral status was tested by non-hepatologists between January 2008 to December 2012. We performed a multivariate analysis to investigate the factors associated with the referral of patients to hepatologists.

Results The rates of hepatitis B virus (HBV) and the percentage of suspected HCV carriers at the hospital were 1.4% and 3.5%, respectively. Among the 727 patients who were seropositive for HBV or HCV, 107 (14.7%) were referred to a hepatologist. A multivariate analysis to investigate the factors contributing to referral revealed that (i) an alanine aminotransferase (ALT) level of >30 IU/L (odds ratio (OR), 3.24; 95% confidence interval (CI), 2.10-5.03; p<0.001); (ii) undergoing testing at an internal medicine department (OR, 2.79; 95% CI, 1.80-4.38; p<0.001); and (iii) HBsAg-positivity (OR, 2.22; 95% CI, 1.35-3.61; p=0.002) were factors that significantly influenced referral.

Conclusion Hepatologists must educate non-hepatologists, especially non-internists, to promote the referral of hepatitis-virus carriers, especially HCV carriers, even in patients with ALT levels of <30 IU/L.

Key words: hepatitis virus carriers, medical collaboration, non-hepatologist, HBV, HCV

(Intern Med 56: 1943-1948, 2017) (DOI: 10.2169/internalmedicine.56.8249)

Introduction

The prevalence rates of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in Japan are estimated to be 0.71% and 0.63%, respectively (1). As HBV and HCV are major causes of cirrhosis, liver failure, and liver cancer, the initiation of appropriate treatment is important for achieving a better prognosis (2, 3).

Although recent advances in antiviral therapy have caused dramatic improvements in the treatment of hepatitis virus infection, only a minority of HBV- or HCV-infected patients receive treatment due to multiple barriers, including patient factors (e.g., ongoing drug or alcohol abuse or psychiatric contraindications), provider factors (e.g., the physician’s lack of knowledge or a reluctance to treat past drug abusers), and system factors (e.g., referral-associated delays or a lack of funds) (4-12). In addition, treated patients are significantly more likely to be referred to a hepatologist, in comparison to untreated patients (11). A previous study indicated that developing collaboration between specialists and primary care providers had the potential to improve the quality of...
HCV care (13). However, little attention has been paid to the actual collaboration between hepatologists and non-hepatologists in the hospital setting.

The Hakujyuji Hospital provides health care for an almost exclusively urban population of 1,500,000 inhabitants. The medical departments within the hospital function independently. The aims of the present study were to determine the proportion of hepatitis B surface antigen (HBsAg)-positive and anti-HCV-positive patients, and identify the characteristics of the patients who were referred (or not referred) to hepatologists in order to provide information for future interventions and to improve the rate of referral.

Materials and Methods

This retrospective study included the patients who tested positive for HBsAg and/or anti-HCV at our hospital over the 5 years from January 2008 to December 2012. Patients who were both HBsAg and anti-HCV-positive were excluded from the assessment of the effect of the virus type on referral. Patients who were already being tested and managed by hepatologists were excluded from the study. Ethical approval was obtained from the ethics committee of the hospital.

HBsAg was detected using the Architect-HBsAg QT assay (Abbott Laboratories, Tokyo, Japan); the cutoff level was 0.05 IU/mL. Anti-HCV was detected using the Architect-HCV assay (Abbott Laboratories); the cutoff point was a signal to cut-off ratio of 1.0.

The patients were classified into two groups: those who were referred to hepatologists (referrals) and those who were not referred to hepatologists (non-referrals). We retrospectively collected the following 12 characteristics of these patients: sex, age on the day of the test, the department in which the viral status was tested (internal medicine or a non-internal medicine department), the physician’s years of experience on the date of the test, the presence of a family doctor (present or absent), platelet count, prothrombin time (%), viral hepatitis markers (HBsAg and anti-HCV), and the serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), and total bilirubin.

The internal medicine departments at our hospital included Diabetes, Neurology, Gastroenterology, Nephrology, Cardiology, Hematology, and Endocrinology. The non-internal medicine departments included General and Gastroenterological Surgery, Breast Surgical Oncology, Orthopedic Surgery, Plastic Reconstructive Surgery, Neurosurgery, Urology, Ophthalmology, Oral Surgery, Physical Medicine, and Rehabilitation. The presence of a family doctor was determined by reviewing the patients’ electronic medical records; “present” was defined by management of the patient’s hepatic condition at another clinic, and absent was defined by the absence of another location of management. The most recent blood test result at the time of viral testing was included in the analysis.

In addition, we used the aforementioned data to create a decision tree from the factors that were found to affect referral to a hepatologist and performed a data mining analysis to further determine the reasons for referral.

The differences in the baseline characteristics of the groups were analyzed using Wilcoxon’s signed test for continuous variables and Pearson’s chi-squared test for categorical variables. A multivariate analysis was performed using stepwise logistic regression models. p values <0.05 were considered to indicate statistical significance. All of the analyses were performed using the JMP software program (version 10; SAS Institute, Cary, NC).

Results

The prevalence of HBsAg or anti-HCV seropositivity

Among the 11,823 patients who were tested for HBsAg, 163 (1.4%) tested positive. Among the 11,320 patients who were tested for anti-HCV, 584 (5.2%) tested positive. Ten patients were positive for both HBsAg and anti-HCV (Fig. 1).

The referral status and the characteristics of the seropositive patients

The overall referral rate for seropositive patients was 14.7% (107/727). The referral rates for HBsAg-positive and anti-HCV-positive patients were 20.9% (32/153) and 13.1% (75/574), respectively (Fig. 1, 2). Among the 75 anti-HCV-positive patients who were referred to a hepatologist, 47 patients whose general condition could be treated with antiviral therapy or who did not have liver cancer or cirrhosis underwent an HCV RNA test; HCV RNA was detected in the serum of 32 patients (68.1%) by a polymerase chain reaction. Eighteen of these 32 (54.3%) patients were infected with non-1 HCV genotypes. The patients in the referral group were significantly younger than those in the non-referral group (Table 1). The rate of referral from internal medicine departments was significantly higher than that from non-internal medicine departments. The serum AST, ALT, and GGT levels were significantly higher and the platelet count was significantly lower in the referral group. A significantly greater number of patients in the referral group were HBsAg-positive, while significantly fewer were anti-HCV-positive.

The multivariate analysis showed that hepatitis virus-positive patients were referred to a hepatologist from a non-hepatologist based on the following factors: an ALT level of $\geq$31 IU/L (odds ratio [OR], 3.24; 95% confidence interval [CI], 2.10-5.03; p<0.001), undergoing testing in an internal medicine department (OR, 2.79; 95% CI, 1.80-4.38; p<0.001), or HBsAg positivity (OR, 2.22; 95% CI, 1.35-3.61; p=0.002) (Table 2 and Fig. 2).

The data mining analysis

A data mining analysis was performed to assess the reasons why the patients were referred to a hepatologist. The
results are shown in Fig. 3. This analysis classified four subgroups based on the three factors that influenced the decision to refer a patient to a hepatologist. The serum ALT value was selected as the best influential factor. Patients with an ALT level of ≥31 IU/L had a higher referral rate than those with an ALT level of <31 IU/L (25.7% vs. 9.9%, p<0.001). Among the patients with an ALT level of ≥31 IU/L, the type of department was strongly associated with referral. The referral rate of patients who underwent testing at an internal medicine department was higher than that of patients who underwent testing at a non-internal medicine department (38.5% vs. 12.8%, p<0.001). In patients with an ALT level of <31 IU/L, the type of the hepatitis virus was strongly associated with referral. HBsAg-positive patients had a higher referral rate than those who were anti-HCV-positive (17.8% vs. 7.5%, p=0.001). Furthermore, among the four subgroups, most patients had an ALT level of <31 IU/L, and the anti-HCV-positive group had the lowest referral rate.

Discussion

Our study showed that among the patients who were tested for the hepatitis virus by a non-hepatologist at our hospital, 1.4% were HBsAg-positive and 5.2% were anti-HCV-positive. The true rate of HCV positivity among the anti-HCV-positive referrals was 3.5%, because HCV RNA was detected in 68.1% of these patients - which is similar to

Figure 1. A flow chart of patients included in this retrospective study. HBsAg: hepatitis B surface antigen, HCV: hepatitis C virus

Figure 2. The referral rate of hepatitis virus-positive patients to a hepatologist based on an alanine aminotransferase (ALT) level of ≥31 IU/L, undergoing viral testing at an internal medicine department, and hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV) positivity.
the patient had an ALT level of ≥31 IU/L, the upper limit of normal for ALT at our hospital is 30 IU/L - at this cutoff point, the value is flagged in red in electronic medical records to attract the health care providers’ attention. Consequently, non-hepatologists were more likely to refer patients to hepatologists due to high ALT values. Moreover, hepatitis virus carriers with normal ALT levels have a higher risk of cirrhosis and liver cancer in comparison to non-carriers (18–20). Thus, physicians need to be aware that referral to a hepatologist is necessary, even for patients with normal ALT levels.

In the subgroup of patients with an ALT level of ≥31 IU/L, the referral rate among patients who underwent testing in an internal medicine department was higher than that among patients underwent testing in a non-internal medicine department. This may indicate the different reasons for testing patients for hepatitis virus. For instance, internists may tend to perform hepatitis viral testing to identify the cause of liver dysfunction, whereas non-internists may be more likely to perform these tests for preoperative surveillance. This gap in perception by internists and non-internists might have influenced the referral rate.

The referral rate of patients with an ALT level of <31 IU/L, was higher for patients who were HBsAg-positive. It is thought that the physicians were more careful about the management of HBV carriers, because there is a general agreement that the infectious capacity of HBV is stronger than that of HCV. In addition, HBV often causes serious clinical conditions, such as severe hepatitis (21–23). Furthermore, this result showed importance of measures for identifying anti-HCV-positive patients, who have a low referral rate. Given the recent and remarkable progress in the treatment of HCV, these measures will become increasingly necessary in order to identify hepatitis virus carriers in hospitals and determine an appropriate treatment strategy.
The perceived barriers to referral to hepatologists are significantly associated with the physician’s knowledge (10). The findings of the current study suggest that among non-hepatologists, there is a gap in the knowledge of viral hepatitis between internists and non-internists. In particular, there was disparity in recognizing HCV infection in patients with a normal ALT level.

The present study is associated with some limitations. First, this study was retrospective in nature and was conducted at a single institution in Japan. Thus, the results may not be generalizable to other patient settings. Second, the reason for referral (or a lack of referral) by chief doctors to hepatologists was unclear. To improve the referral rate, these reasons should be elucidated.

In conclusion, to improve the current low rate of referral of hepatitis virus carriers, hepatologists should encourage and instruct non-hepatologists, especially non-internists to refer patients with hepatitis virus, especially those who are anti-HCV-positive, to a hepatologist - even if the patient’s ALT level is normal.

The authors state that they have no Conflict of Interest (COI).

References
1. Tanaka J, Koyama T, Mizui M, et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology 54: 185-195, 2011.
2. Lok AS. Chronic hepatitis B. N Engl J Med 346: 1682-1683, 2002.
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 36: S35-S46, 2002.
4. Nguyen VG, Wan K, Trinh HN, Li J, Zhang JQ, Nguyen MH. Chronic hepatitis B treatment eligibility and actual treatment rates in patients in community gastroenterology and primary care settings. J Clin Gastroenterol 49: 145-149, 2014.
5. Falck-Ytter Y, Kale H, Mullen KD, Sarbach SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136: 288-292, 2002.
6. Rowan PJ, Tabasi S, Abdul-Latif M, Kunik ME, El-Serag HB. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 38: 530-534, 2004.
7. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 16: 352-358, 2009.
8. Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 30: 240-250, 2010.
9. Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother 65: 1327-1329, 2010.
10. McGowan CE, Monis A, Bacon BR, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 57: 1325-1332, 2013.
11. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 20: 754-758, 2005.
12. Gheorghe L, Pascu O, Ceausu E, et al. Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009. J Gastrointestin Liver Dis 19: 161-167, 2010.
13. Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med 153: 231-239, 2010.
14. Prieto M, Olaso V, Verdú C, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 22: 413-417, 1995.
15. Tanaka J, Kumagai J, Katayama K, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 47: 32-40, 2004.
16. Kato H, Maeno Y, Seko-Nakamura Y, et al. Identification and phylogenetic analysis of hepatitis C virus in forensic blood samples obtained from injecting drug users. Forensic Sci Int 168: 27-33, 2007.
17. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 53: 39-43, 2010.
18. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 36: S179-S184, 2002.
19. Okanoue T, Makiyama A, Nakayama M, et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 43: 599-605, 2005.
20. Tanaka T, Shakado S, Takata K, et al. Hepatitis C virus-infected patients with persistently normal alanine aminotransferase levels whose platelet count less than 150,000/μL and whose age over 55 years old should be recommended antiviral therapy. Med Bull Fukuoka Univ 39: 103-112, 2012.
21. Alter HJ, Seeff LB, Kaplan PM, et al. Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med 295: 909-913, 1976.
22. Shikata T, Karasawa T, Abe K, et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 136: 571-576, 1977.
23. Feinstone SM, Alter HJ, Dienes HP, et al. Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis 144: 588-598, 1981.